Pre-clinical investigation reveals MBQ-167 alters immune response in triple negative breast cancer, suggesting therapeutic potential.
Key Points
This research aims to evaluate the effects of MBQ-167 on the breast tumor immune microenvironment and its potential as a therapeutic agent for triple negative breast cancer (TNBC).
Administered MBQ-167 to Balb/C mice with 4T-1 TNBC tumors
Performed immunophenotyping of spleens and tumors
Conducted ELISAs for cytokine levels in tumor-conditioned media and mouse plasma
Used gene set enrichment analysis to assess transcriptomic changes
MBQ-167 treatment reduced M2 macrophages and myeloid-derived suppressor cells (MDSCs) while increasing CD8+ T cells
Significant decrease in IL-6 levels in mouse plasma post-treatment
Downregulation of inflammatory mediators CHI3L1 and S100A8/A9 in treated tumors
80% reduction in tumor growth observed with MBQ-167 without toxic effects
MBQ-167 was more effective than anti-PD1 or anti-PDL1 therapies in this model.
Cite This Study
Torres-Sanchez et al. (2026) studied this question.